Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by Sumitomo Mitsui Trust Group Inc.

Sumitomo Mitsui Trust Group Inc. lessened its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 2.1% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 318,608 shares of the biopharmaceutical company’s stock after selling 6,771 shares during the period. Sumitomo Mitsui Trust Group Inc. owned about 0.24% of Alnylam Pharmaceuticals worth $78,613,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Wellington Management Group LLP boosted its holdings in Alnylam Pharmaceuticals by 9.0% in the 2nd quarter. Wellington Management Group LLP now owns 2,110,407 shares of the biopharmaceutical company’s stock worth $635,296,000 after acquiring an additional 174,482 shares during the period. Legal & General Group Plc purchased a new stake in shares of Alnylam Pharmaceuticals during the second quarter valued at approximately $278,321,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Alnylam Pharmaceuticals by 7.4% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 727,848 shares of the biopharmaceutical company’s stock worth $219,104,000 after purchasing an additional 50,329 shares in the last quarter. Bank of New York Mellon Corp purchased a new position in shares of Alnylam Pharmaceuticals in the second quarter valued at $148,128,000. Finally, Swiss National Bank boosted its stake in shares of Alnylam Pharmaceuticals by 7.9% in the first quarter. Swiss National Bank now owns 387,720 shares of the biopharmaceutical company’s stock valued at $128,285,000 after purchasing an additional 28,520 shares during the period. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Trading Up 1.2%

NASDAQ:ALNY opened at $159.89 on Wednesday. The company has a debt-to-equity ratio of 0.18, a current ratio of 2.48 and a quick ratio of 2.43. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $156.00 and a fifty-two week high of $479.79. The stock’s 50-day moving average is $233.41 and its two-hundred day moving average is $284.10. The stock has a market cap of $21.42 billion, a PE ratio of 8.30 and a beta of 0.42.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, October 29th. The biopharmaceutical company reported $16.26 EPS for the quarter, topping the consensus estimate of $1.66 by $14.60. Alnylam Pharmaceuticals had a net margin of 52.85% and a return on equity of 155.33%. The company had revenue of $1.46 billion during the quarter, compared to the consensus estimate of $1.43 billion. During the same period in the previous year, the firm posted $2.90 earnings per share. The company’s revenue for the quarter was up 16.7% compared to the same quarter last year. As a group, equities research analysts forecast that Alnylam Pharmaceuticals, Inc. will post 6.58 earnings per share for the current fiscal year.

Trending Headlines about Alnylam Pharmaceuticals

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Alnylam plans to present five-year HELIOS-B results and additional clinical and real-world evidence on AMVUTTRA (vutrisiran) at conferences in November. The presentations could provide new information about the treatment’s potential, though the announcement did not include new study results. Alnylam conference presentation announcement
• Negative Sentiment: Analyst sentiment weakened: Raymond James cut its rating from Strong Buy to Outperform, while Bernstein moved from Outperform to Market Perform. Raymond James downgrade Bernstein downgrade
• Negative Sentiment: Price expectations have also been trimmed: the consensus target fell 13.64% to $325.18, and Truist lowered its target to $225 from $315 while cutting its rating to Hold. Although the targets remain above the share price cited in the reports, the reductions signal increased caution. Consensus target reduction

Analyst Ratings Changes

A number of brokerages have commented on ALNY. Citigroup cut their price objective on shares of Alnylam Pharmaceuticals from $340.00 to $320.00 and set a “buy” rating on the stock in a report on Wednesday, October 14th. Oppenheimer reduced their target price on Alnylam Pharmaceuticals from $350.00 to $320.00 and set an “outperform” rating for the company in a research note on Friday, October 30th. Weiss Ratings restated a “hold (c)” rating on shares of Alnylam Pharmaceuticals in a research note on Thursday, October 29th. Cantor Fitzgerald reiterated a “neutral” rating on shares of Alnylam Pharmaceuticals in a research note on Wednesday, September 30th. Finally, TD Cowen decreased their price objective on shares of Alnylam Pharmaceuticals from $482.00 to $354.00 and set a “buy” rating for the company in a report on Friday, October 30th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $305.86.

Insider Buying and Selling

In other news, EVP Bryan Supran sold 1,758 shares of the company’s stock in a transaction dated Friday, October 2nd. The stock was sold at an average price of $226.88, for a total transaction of $398,855.04. Following the completion of the sale, the executive vice president owned 12,807 shares in the company, valued at approximately $2,905,652.16. This represents a 12.07% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 0.86% of the stock is owned by insiders.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines based on RNA interference (RNAi). The company’s therapies are designed to silence specific genes involved in disease, with the goal of addressing the underlying causes of genetic and other serious conditions.

Alnylam’s marketed products include ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1.